Overview and Implications: The Food And Drug Administration's Proposal to Permit Generic Drug Manufacturers to Initiate Labeling Changes

HHS Finalizes New Protections Under the Stark Law for Value-Based Arrangements and Makes Other Critical Revisions and Clarifications to the Regulations that Physicians and Designated Health Service Entities Must Understand

HHS Finalizes New Protections for Value-Based Arrangements and Other Revisions to the Anti-Kickback Statute Safe Harbors and Civil Monetary Penalties Exceptions